SCHEMBL29629209

SCHEMBL29629209

CCNc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCOCC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 7/20 0.52
CCNC P24863 4/20 0.52
CDK9 P50750 4/20 0.51
CDK2 P24941 4/20 0.51
AURKA O14965 3/20 0.51
AURKB Q96GD4 3/20 0.51
CDK4 P11802 2/20 0.51
ABL1 P00519 4/20 0.47
NTRK1 P04629 2/20 0.47
NTRK2 Q16620 2/20 0.47
TEK Q02763 1/20 0.47
RET P07949 3/20 0.47
KDR P35968 4/20 0.46
CDK7 P50613 2/20 0.46
FGFR1 P11362 2/20 0.46
WEE1 P30291 2/20 0.46
FLT3 P36888 2/20 0.46
ALK Q9UM73 2/20 0.46
CHEK1 O14757 1/20 0.46
DAPK3 O43293 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23068679 1.00 CDK8 (0.52) CDK8CCNCCDK9CDK2AURKA
SCHEMBL23068680 0.93 CDK8 (0.60) CDK8CCNCCDK9CDK2AURKA
SCHEMBL29629228 0.93 CDK8 (0.60) CDK8CCNCCDK9CDK2AURKA
SCHEMBL23068654 0.93 RET (0.55) CDK8CCNCCDK9CDK2AURKA
SCHEMBL29629256 0.93 RET (0.55) CDK8CCNCCDK9CDK2AURKA
SCHEMBL23068639 0.92 EGFR (0.54) CDK8CCNCCDK2ABL1NTRK1
SCHEMBL29629211 0.92 EGFR (0.54) CDK8CCNCCDK2ABL1NTRK1
SCHEMBL22684881 0.91 CDK8 (0.47) CDK8CCNCCDK9CDK2AURKA
SCHEMBL23068622 0.91 CDK8 (0.54) CDK8CCNCCDK9CDK2AURKA
SCHEMBL29629236 0.91 CDK8 (0.54) CDK8CCNCCDK9CDK2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP disclosed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN disclosed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 CDK8 1/4885CCNC 38/4885CDK9 3/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 CDK8 1/4885CCNC 38/4885CDK9 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.